News & Updates

Show Multimedia Only

Overdose risk higher with concomitant use of Z-Drugs, prescription opioids

13 Aug 2021

Treatment with Z-drugs (zolpidem, zopiclone, zaleplon) appears to result in a marked increase in the risk of overdose among patients receiving prescription opioids, reveals a recent study. The potential implications are noteworthy due to the large number of opioid-treated patients using Z-drugs.

Overdose risk higher with concomitant use of Z-Drugs, prescription opioids

13 Aug 2021

Concomitant antidementia drug use does not affect pimavanserin safety, PK profile

13 Aug 2021 by

In patients with neurodegenerative and/or neurovascular disease (NDD) and dementia-related psychosis (DRP), concomitant antidementia medications (cADMs) used alongside the selective serotonin receptor modulating agent pimavanserin did not adversely impact its safety and pharmacokinetic (PK) profile, according to data presented at AAIC 2021.

Concomitant antidementia drug use does not affect pimavanserin safety, PK profile

13 Aug 2021

Depression no longer a barrier to DAA initiation for patients with HIV-HCV

12 Aug 2021 by

Despite having depressive symptoms, treatment initiation rates seem to be improving among patients coinfected with HIV and hepatitis C virus (HCV), according to a study presented at the recently concluded 2021 International AIDS Society Conference on HIV Science (IAS 2021).

Depression no longer a barrier to DAA initiation for patients with HIV-HCV

12 Aug 2021

News & Updates

Showing Psychiatry articles

Showing

Specialty:

Overdose risk higher with concomitant use of Z-Drugs, prescription opioids

Overdose risk higher with concomitant use of Z-Drugs, prescription opioids

Concomitant antidementia drug use does not affect pimavanserin safety, PK profile

Concomitant antidementia drug use does not affect pimavanserin safety, PK profile

Depression no longer a barrier to DAA initiation for patients with HIV-HCV

Depression no longer a barrier to DAA initiation for patients with HIV-HCV